Boehringer to sell vaccine lines to Elanco

The transaction is valued at $885 million

Elanco Animal Health plans to acquire more than 40 vaccines from Boehringer Ingelheim Vetmedica Inc. in a transaction valued at $885 million, the companies announced today.

The purchase consists of Boehringer’s entire U.S. portfolio of feline, canine and rabies vaccines and the company’s Fort Dodge, Iowa, manufacturing plant and laboratory.

The agreement is subject to regulatory approval but is expected to conclude in early 2017.

The deal follows a move late last year by parent company Boehringer Ingelheim to merge with veterinary drug maker Merial and sell most of Boehringer’s human drug business to Merial owner Sanofi S.A. The sale of the Fort Dodge facility to Elanco helps clear the way for the $5.2 billion Merial takeover, which is expected to close in the coming weeks.

“This was a highly complex decision from a business and from an emotional perspective,” said Albrecht Kissel, president and CEO of St. Joseph, Mo.-based Boehringer Ingelheim Vetmedica.

“We are confident that, under Elanco’s leadership, customers will continue to have access to these innovative vaccines and the portfolio will have strong support,” Kissel said.

Boehringer would retain ownership of pet drugs such as Metacam and Vetmedin for dogs and Metacam and ProZinc for cats as well as cattle, equine and swine products.

Elanco, headquartered in Greenfield, Ind., makes pharmaceuticals for companion animals and livestock. Its pet drugs include the spot-on feline flea preventive Cheristin and the canine flea and heartworm medication Trifexis.

“As a result of the acquisition, Elanco will bring greater value to customers by providing a suite of options for preventing common diseases in companion animals,” said John C. Lechleiter, Ph.D., the president and CEO of Elanco owner Eli Lilly and Co.

“Coupled with our robust food animal portfolio, this addition further strengthens Elanco’s position in the global animal health business,” Lechleiter added.

Elanco would take possession of Boehringer’s newest offering: Ultra Duramune Lyme, a 0.5-milliliter Lyme disease vaccine for dogs, which was unveiled Tuesday.

What Elanco Would Get

Canine Duramune Line

  • Duramune Max 5/4L
  • Duramune Max 5
  • Duramune Max 5-Cvk/4L
  • Duramune Max 5-Cvk
  • Duramune Max Pv
  • Duramune Cv-K
  • Duramune Max PC
  • Duramune Adult 3
  • LeptoVax 4
  • LeptoVax 4/C

Canine Bronchi-Shield line

  • Bronchi-Shield Oral
  • Bronchi-Shield III

Canine Duramune Lyme line

  • Duramune Lyme
  • Duramune Lyme + LeptoVax 4
  • Duramune Lyme + Max 5/4L
  • Duramune Lyme + Max5-CvK/4L
  • Duramune Lyme + Max5-CvK
  • Duramune Lyme + Leptovax 4/C

Canine Ultra Duramune line

  • Ultra Duramune DAP+4L
  • Ultra Duramune DAP
  • Ultra Duramune 4L
  • Ultra Duramune DAP+C4L
  • Ultra Duramune DAP+C
  • Ultra Duramune Lyme

Feline Fel-O-Vax line

  • Fel-O-Vax Lv-K IV + CaliciVax
  • Fel-O-Vax Lv-K III + CaliciVax
  • Fel-O-Vax Lv-K
  • Fel-O-Vax IV + CaliciVax
  • Fel-O-Vax PCT + CaliciVax
  • Fel-O-Vax Lv-K + FIV
  • Fel-O-Vax FIV
  • CaliciVax

Feline Ultra Fel-O-Vax line

  • Ultra Fel-O-Vax FVRCP+FeLV
  • Ultra Fel-O-Vax FVRCP
  • Ultra Fel-O-Vax FeLV
  • Ultra Fel-O-Vax Dual FCV
  • Ultra Hybrid FVRCP

Feline Fel-O-Guard line

  • Fel-O-Guard Plus 3
  • Fel-O-Guard Plus 3 + Lv-K
  • Fel-O-Guard Plus 4
  • Fel-O-Guard Plus 4 + Lv-K

Rabies

  • Rabvac 3
  • Rabvac 1
Leave a Comment

Comments

Your email address will not be published. Required fields are marked *

___

Register

Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).
 

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.